These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 37164738)
21. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666 [No Abstract] [Full Text] [Related]
29. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. McLean LP; Cross RK Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357 [TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971 [TBL] [Abstract][Full Text] [Related]
31. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis. Hagan M; Cross RK Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111 [TBL] [Abstract][Full Text] [Related]
32. Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis. Rizos ED; Antonogiannaki EM; Chatzidakis A; Kallieri M; Tsilogianni Z; Manali ED; Economopoulos N; Triantafyllou K; Papiris SA; Polymeros D Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1057-e1059. PubMed ID: 34074983 [TBL] [Abstract][Full Text] [Related]
33. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095 [TBL] [Abstract][Full Text] [Related]
34. The safety of vedolizumab for the treatment of ulcerative colitis. Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855 [TBL] [Abstract][Full Text] [Related]
35. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease]. Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456 [TBL] [Abstract][Full Text] [Related]
36. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? D'Amico F; Danese S; Peyrin-Biroulet L Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748 [No Abstract] [Full Text] [Related]
38. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803 [TBL] [Abstract][Full Text] [Related]
39. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. Cohen RD; Bhayat F; Blake A; Travis S J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340 [TBL] [Abstract][Full Text] [Related]
40. Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. Ma C; Kotze PG; Almutairdi A; Jairath V; Panaccione R Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2374-2376.e2. PubMed ID: 30528845 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]